Relmada acquires neurosteroid from Asarina
Relmada in-licenses Tourette syndrome drug from Asarina
US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from Sweden’s Asarina Pharma, being developed for the potential treatment of Tourette syndrome (TS) and other compulsive disorders.
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...
This page features the latest news about the Relmada Therapeutics stock. RLMD stock touches 52-week low at $0.35 amid market challenges In a turbulent market environment, Relmada Therapeutics Inc ...
Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals.
Relmada Therapeutics, Inc. has recently received a notice from the Nasdaq Stock Market indicating that the company’s security did not maintain a minimum bid price of $1 per share for the 30 ...
Relmada Therapeutics, Inc. (RLMD) stock price is 0.34 and Relmada Therapeutics, Inc. (RLMD) 10-day simple moving average is 0.37. Relmada Therapeutics, Inc. (RLMD) stock price is 0.34 and ...
In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at just $0.34. According to InvestingPro data, the company maintains a strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback